Inventor · disambiguated record
Fuqiang Jin
Also filed as: JIN FUQIANG
9 granted patents·2 pending applications·258 citations·filing 1996–2005
89Inventor score
Files withDU PONT PHARM CO4BRISTOL MYERS SQUIBB PHARMA CO2DU PONT MERCK PHARMA1PHARMASSET INC1PHARMASSET LTD1
Top patents by PatentIndex Score
11 records- 0195US6927291B2Method for the synthesis of 2′,3′-dideoxy-2′,3′-didehydronucleosidesPHARMASSET LTD·Filed 2002·Granted Aug 9, 2005·100 cites·60 claims
- 0291US5668159A1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonistsDU PONT MERCK PHARMA·Filed 1996·Granted Sep 16, 1997·68 cites·12 claims
- 0380US6667332B2Efficient process for the preparation of a factor Xa inhibitorBRISTOL MYERS SQUIBB PHARMA CO·Filed 2001·Granted Dec 23, 2003·11 cites·35 claims
- 0480US6153628A1,3,4-thiadiazoles and 1,3,4-Oxadiazoles as αv β3 antagonistsDU PONT PHARM CO·Filed 1998·Granted Nov 28, 2000·53 cites·8 claims
- 0571US6747158B2Efficient process for the preparation of a factor Xa inhibitorBRISTOL MYERS SQUIBB PHARMA CO·Filed 2003·Granted Jun 8, 2004·4 cites·25 claims
- 0671US6562963B2Process for the preparation of macrocyclic metalloprotease inhibitorsFiled 2001·Granted May 13, 2003·6 cites·14 claims
- 0755US6004955ACyclic carbamates and isoxazolidines as IIb/IIIa antagonistsDU PONT PHARM CO·Filed 1998·Granted Dec 21, 1999·6 cites·8 claims
- 0854US2004198787A1Efficient process for the preparation of a factor Xa inhibitorFiled 2004·Application pending·0 cites
- 0952US6307044B1Process for the preparation of macrocyclic metalloprotease inhibitorsDU PONT PHARM CO·Filed 1999·Granted Oct 23, 2001·10 cites·22 claims
- 1052US2005250946A1Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosidesPHARMASSET INC·Filed 2005·Application pending·0 cites
- 1131US6265400B1Cyclic carbamates and isoxazolidines as IIb/IIIa antagonistsDU PONT PHARM CO·Filed 1999·Granted Jul 24, 2001·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Fuqiang Jin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →